SAROGLITAZAR IS A DUAL REGULATOR THAT CORRECTS BOTH THE LIPID PROFILE & THE GLYCEMIC INDICES. IT IS A POTENT & PREDOMINANTLY PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR)-ALPHA AGONIST WITH MODERATE PPAR-GAMMA AGONISTIC ACTIVITY. PPAR ARE NUCLEAR LIPID ACTIVATED TRANSCRIPTION FACTORS THEAT REGULATE THE EXPRESSION OF VARIOUS GENES INVOLVED IN THE CONTROL OF LIPID & LIPOPROTEIN METABOLISM, GLUCOSE HOMEOSTASIS & INFLAMMATORY PROCESSES. IT DECREASES THE POSTPRADIAL RISE OF PLASMA FREE FATTY ACIDS, IMPROVES POST-ABSORPTIVE INSULIN MEDIATED SUPPRESSION OF HEPATIC GLUCOSE OUTPUT, REDUCES THE METABOLIC BURDEN ON LIVER & MUSCLE & PROMOTES GLUCOSE UTILIZATION. IT IMPROVES INSULIN RESISTANCE.